Objective To observe the efficacy of lamivudin (LAM) e and adefovir diplvoxil ( ADV) combination therapy with Fuzheng Huayu Capsule for patients with hepatitis B virus-related decompensated drrhosis for 2 years. Methods A total of 51 patients with HBV-related cirrhosis were erolled in this study. They were randomly divided into 2 groups; the treatment group (n =30) received LAM and ADV combination therapy with Fuzheng Huayu Capsule for 2 years; the control group ( n =21 ) received general liver-protection. The change of serum liver fibrosis index, portal vein inner diameter, spleen thickness, HBV DNA and Child-Pugh score were observed. Results After 2 years, the HBV DNA level decreased more in the treatment groups (82. 8% , on the said index 24/29) than that in control group (11.1% ,2/18). No renal dysfunction was observed in both groups. Conclusion LAM and ADV combined with Fuzheng Huayu Capsule is bette choice for patients with HBV-related decompensated cirrhosis.%目的 观察拉米夫定、阿德福韦酯联合扶正化瘀胶囊对于乙肝后肝硬化失代偿期治疗作用.方法 将51例乙肝后肝硬化失代偿期患者随机分为两组.对照组(n=21)用常规西药治疗方法,如维生素类和护肝降酶治疗,必要时用人血白蛋白等;治疗组(n=30)给予拉米夫定、阿德福韦酯联合扶正化瘀胶囊,疗程均为2年.观察治疗前后HBV-DNA载量,Child-Pugh评分,透明质酸(HA)、Ⅲ型前胶原肽( PcⅢ)、Ⅳ型胶原(Ⅳ-C)和层黏蛋白(LN)等血清肝纤维化指标,彩色多普勒检查肝脾形态、门静脉内径(Dpv)、脾静脉内径(Dsv)和脾厚度(st).结果 基线时两组以上观察指标均无统计学差异(P＞0.05).治疗结束时,对照组3例死亡(肝癌1例、上消化道出血 2例),自身前后对比疗效改善不明显((P＞0.05).治疗组死亡1例(交通意外),自身前后对比观察指标改善优于对照组(p＜0.05).结论 拉米夫定、阿德福韦酯联合扶正化瘀胶囊有明显改善乙肝后肝硬化失代偿期Child-Pugh评分作用和肝脾形态,降低HBV DNA水平.
展开▼
